MSHLPertuzumab Concentrate For Solution For Infusion 420 mg/14 mL
1) Pertuzumab in combination with trastuzumab and chemotherapy for HER2-positive metastatic or locally recurrent breast cancer, in patients without prior treatment for metastatic disease. Treatment with pertuzumab should be stopped if disease progresses.
2) Pertuzumab in combination with trastuzumab and chemotherapy for adjuvant treatment of high-risk (with positive nodes) HER2 positive early breast cancer for a maximum duration of 1 year.
3) Pertuzumab in combination with trastuzumab and chemotherapy for neoadjuvant treatment of HER2 positive locally advanced, inflammatory or early stage (tumour >2 cm in diameter or node positive) breast cancer for 4 to 6 cycles. Following surgery, patients may continue with trastuzumab with or without pertuzumab for a total of 1 year of anti-HER2 treatment.